A Resource Guide to Investing in Biotechnology
Directory - Encyclopedia - Stock Index - Drugs  

Biotech100 Stock Index


About Pharmacyclics

Pharmacyclics, Inc. is a pharmaceutical company developing a patented new class of drugs intended to treat cancer and atherosclerosis. The pharmaceutical agents, known as texaphyrins, are synthetic small molecules designed to possess a variety of biological and chemical properties.

Texaphyrins are designed to selectively concentrate in diseased tissue such as tumor cells and atherosclerotic plaque inside blood vessels. Inside diseased cells, texaphyrins block crucial steps in cellular metabolism and disrupt bioenergetic processes.



Motexafin gadolinium --this is the company's lead anti-cancer product candidate, currently is in Phase 3 clinical trials. It has potentially broad applications in oncology and is designed to: selectively target cancer cells; and be detected by magnetic resonance imaging (MRI) allowing visualization of the drug in tumors.

Motexafin lutetium -- Pharmacyclics is investigating the potential of texaphyrin treatment, including the combination of motexafin lutetium and interventional delivery of light-based therapy, to reduce or eliminate “vulnerable plaque,” the cause of serious cardiac events.




Home Page

Key Statistics for Pharmacyclics

Basic Chart for Pharacyclics

Analyst Opinion

Analysts Estimates


Biotech100 Index
· What are the Requirements to be listed in the Biotech100 Index?
· See the Biotech100 List

Sponsored Links

Clinical Trials
· What is a Clinical Trial?
·Phase I ,-- Phase II, -- PhaseIII
·What is Randomized Control?
 What is a Double Blind Experiment?
·What is the role of the FDA?


Key Biotech Terms


Biotech Resources


Investing in Stocks
· Small Cap Stocks
· Stocks and Bonds
· Biotech100 Index

Careers and Employment
· Biotechnology and Pharmaceutical
· What are the Fastest Growing Careers?




Copyright © 2005 BIOTECH100.COM. All rights reserved.